NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has announced the successful closing of its underwritten public offering, which included common stock, pre-funded warrants, and Series F-1, F-2, and F-3 warrants, raising approximately $3.87 million before underwriting discounts and expenses. This total…
Battelle, renowned for its extensive expertise in research, laboratory analysis, and consulting on Per- and Polyfluoroalkyl Substances (PFAS), is now leveraging its skills in response to the growing awareness and regulation of these chemicals. With increasing federal regulations like the…
Tandem Diabetes Care and Dexcom Announce Compatibility of t:slim X2 Insulin Pump with Dexcom G7 CGM in Canada Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM) have announced that the updated software for the t:slim X2™ insulin…
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that it has received New Drug Application (NDA) approval from the U.S. Food and Drug Administration (FDA) for its new potassium phosphates in 0.9% sodium chloride IV bags. This new ready-to-use (RTU) sterile…
Good Neighbor Pharmacy, a national network under Cencora, celebrated independent pharmacy excellence at its annual conference, ThoughtSpot 2024, held from July 24-27 at the Marriott World Center in Orlando, Fla. Now in its 13th year, ThoughtSpot gathered over 3,500 pharmacy…
Centene Corporation (NYSE: CNC) has announced its financial results for the second quarter ending June 30, 2024. Here’s a summary of the key figures: Note: Adjusted EPS and SG&A Expense Ratios are non-GAAP financial measures. Reconciliations are available in the…
HCA Healthcare, Inc. (NYSE: HCA) reported its financial and operational results for Q2 2024, ending June 30, 2024. Here are the key highlights: Second Quarter Highlights: Six-Month Summary: Balance Sheet & Cash Flow: Dividend Declaration: Revised 2024 Guidance: Outlook:The revised…
CVS Caremark®, the top pharmacy benefit manager and a division of CVS Health® (NYSE: CVS), has announced a new commitment to enhance pharmacy benefits for American businesses, unions, and health plans. This initiative aims to offer greater transparency, lower drug…
Bristol Myers Squibb (NYSE: BMY) has announced its financial results for Q2 2024. Highlights: Second Quarter Financials: Product Revenue Highlights: Product and Pipeline Updates: Financial Guidance for 2024: Bristol Myers Squibb’s Q2 2024 results reflect ongoing efforts to drive growth…
Geron Corporation (Nasdaq: GERN) has announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include RYTELO™ (imetelstat) as a recommended treatment for symptomatic anemia in lower-risk myelodysplastic syndromes (MDS). The updated guidelines categorize RYTELO…
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced a new study in the Journal of Clinical Oncology showcasing the effectiveness of its personalized molecular residual disease (MRD) test, Signatera, for monitoring Merkel cell carcinoma (MCC). The…
HU Group Holdings Inc. and its subsidiary, Fujirebio, have announced the launch of the Lumipulse G GFAP assay for use on the fully automated, random-access LUMIPULSE® G immunoassay systems. This research-use only (RUO) assay is now available in the United…